title: Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression.
abstract: OBJECTIVE
  p63, a gene that shares structural and functional homologies with p53, codes for different isoforms, with (TA) and without (DeltaN) transactivating properties. The anti-apoptotic DeltaN isoform is often expressed in breast cancer (BC). DNA damaging drugs such as cisplatin (C) induce its degradation and stabilization of the TA, proapoptotic isoform. This supports the role of these drugs in the treatment of tumors expressing p63. The aim of the present study was to ascertain the predictive value of p63 immunoreactivity in patients treated preoperatively with regimens including cisplatin and/or anthracyclines.
  
  
  METHODS
  We reviewed the pretreatment biopsies of 189 patients with large or locally advanced BC (cT1-4d, N0-2, M0) treated with preoperative chemotherapy, performing p63 immunohistochemistry. The rate of pathological complete remission (pCR) at final surgery was assessed with respect to cisplatin administration and p63 immunoreaction.
  
  
  RESULTS
  pCR was identified in 20 patients (11%); 147 patients (78%) had an objective response, 39 (21%) stable disease, and 3 (1%) disease progression. One hundred forty seven patients (78%) received a cisplatin-containing regimen. Only regimens including cisplatin without anthracyclines yielded a higher rate of pCR in p63-positive compared with p63-negative tumors (23 vs. 0%, P=0.048). No significant difference in the pCR rate was observed for regimens containing anthracycline without cisplatin.
  
  
  CONCLUSIONS
  Administration of cisplatin without anthracyclines correlates with a high rate of pCR after primary chemotherapy in patients with p63-positive BC. The role of cisplatin-based chemotherapy should be further studied in these patients.
authors.affiliation: Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy. andrea.rocca@ieo.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Rocca
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Viale
authors.forename: Richard D
authors.initials: RD
authors.lastname: Gelber
authors.forename: Luca
authors.initials: L
authors.lastname: Bottiglieri
authors.forename: Shari
authors.initials: S
authors.lastname: Gelber
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Pruneri
authors.forename: Raffaella
authors.initials: R
authors.lastname: Ghisini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Balduzzi
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Pietri
authors.forename: Claudia
authors.initials: C
authors.lastname: D'Alessandro
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
authors.forename: Marco
authors.initials: M
authors.lastname: Colleoni
mesh_terms: D018943:Anthracyclines / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D008565:Membrane Proteins / Q000096:biosynthesis* / Q000235:genetics; D011237:Predictive Value of Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D002945:Cisplatin; D019394:Ki-67 Antigen; D008565:Membrane Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C081876:CKAP4 protein, human